Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.39 (1.00%)
Data as of 07/21/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
05/30/17The Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including Late-Stage Investigational Antibiotic Meropenem-Vaborbactam
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 30, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products and late-stage product candidates will be featured in presentations at the American Society for Microbiology’s ASM Microbe 2017 to be held June 1-5, 2017 in New Orleans. The Medicines Company’s infectious disease research and product development is focused on the most serious multi-drug resist... 
Printer Friendly Version
05/04/17The Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 4, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Bank of America Merrill Lynch 2017 Health Care Conference on Tuesday, May 16, 2017, in Las Vegas, Nevada. Clive Meanwell, M.D., Ph.D., Chief Executive Officer, will participate in a fireside chat at 8:00 a.m., Pacific Daylight Time. A live audio webcast will be available in the “Investors-Events/Presentations... 
Printer Friendly Version
04/26/17The Medicines Company Reports First-Quarter 2017 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 26, 2017-- The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the first-quarter ended March 31, 2017. “During the first quarter of 2017, The Medicine Company continued to deliver excellent execution against our 2017 objectives, significantly advancing key development programs, strictly managing cash deployment to enhance our ability to support our products and pipelin... 
Printer Friendly Version
04/26/17The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
— Pivotal trials will enroll approximately 1,500 subjects randomized to inclisiran versus approximately 1,500 subjects randomized to placebo, with a primary endpoint of LDL-C and an 18-month study period — — NDA submission anticipated at or around the end of 2019 — PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2017-- The Medicines Company (NASDAQ:MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) today announced that T... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.